The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia
COVID-19 is a major public health problem, with still questionable specific cure. Favipiravir is a COVID-19 antiviral that is potentially a therapy for COVID-19. This study aimed to analyze its effectivity and safety in moderate to critical hospitalized patients. This study was a retrospective cohor...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Indonesia
2021-11-01
|
| Series: | Kesmas: Jurnal Kesehatan Masyarakat Nasional |
| Subjects: | |
| Online Access: | https://journal.fkm.ui.ac.id/kesmas/article/view/5433 |
| _version_ | 1797723949032800256 |
|---|---|
| author | Herni Damayanti I Gede K Sajinadiyasa Hindun Wilda Risni Rani Sauriasari |
| author_facet | Herni Damayanti I Gede K Sajinadiyasa Hindun Wilda Risni Rani Sauriasari |
| author_sort | Herni Damayanti |
| collection | DOAJ |
| description | COVID-19 is a major public health problem, with still questionable specific cure. Favipiravir is a COVID-19 antiviral that is potentially a therapy for COVID-19. This study aimed to analyze its effectivity and safety in moderate to critical hospitalized patients. This study was a retrospective cohort in a tertiary referral hospital in Denpasar City, Bali Province, Indonesia, from August 2020 to January 2021. There was a total of 192 patients; 96 in the favipiravir group and 96in the non-favipiravir group (remdesivir/oseltamivir). Effectivity was measured by assessing the clinical condition at the end of the isolation period of 14 days. The favipiravir group showed better clinical conditions than the non-favipiravir group (79.2% vs. 56.3%; adjusted RR = 2.196; 95% CI = 1.084 – 4.451; p-value= 0.029), seen from being free of fever and respiratory problems. Stratification analysis demonstrated that the clinical improvement was significantly differentin the severe/critical group in favor of favipiravir (RR = 1.573; 95% CI = 1.139-2.172). The most common non-serious adverse events (AE) found in the use offavipiravir were gastrointestinal disturbances (12.5%). In brief, favipiravir is effective in severe/critical cases, and less serious AE were found in its use. Appropriate treatment is expected to help in reducing the public health burden. |
| first_indexed | 2024-03-12T10:10:13Z |
| format | Article |
| id | doaj.art-012c56bbdbe74b139eb4e8850c6b47a7 |
| institution | Directory Open Access Journal |
| issn | 1907-7505 2460-0601 |
| language | English |
| last_indexed | 2024-03-12T10:10:13Z |
| publishDate | 2021-11-01 |
| publisher | Universitas Indonesia |
| record_format | Article |
| series | Kesmas: Jurnal Kesehatan Masyarakat Nasional |
| spelling | doaj.art-012c56bbdbe74b139eb4e8850c6b47a72023-09-02T10:54:54ZengUniversitas IndonesiaKesmas: Jurnal Kesehatan Masyarakat Nasional1907-75052460-06012021-11-0116410.21109/kesmas.v16i4.54331174The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, IndonesiaHerni Damayanti0I Gede K Sajinadiyasa1Hindun Wilda Risni2Rani Sauriasari3Faculty of Pharmacy Universitas Indonesia, Depok 16424, IndonesiaPulmonology Division, Internal Medicine Department, Sanglah General Hospital, Denpasar, IndonesiaFaculty of Pharmacy Universitas Indonesia, Depok 16424, IndonesiaFaculty of Pharmacy Universitas Indonesia, Depok 16424, IndonesiaCOVID-19 is a major public health problem, with still questionable specific cure. Favipiravir is a COVID-19 antiviral that is potentially a therapy for COVID-19. This study aimed to analyze its effectivity and safety in moderate to critical hospitalized patients. This study was a retrospective cohort in a tertiary referral hospital in Denpasar City, Bali Province, Indonesia, from August 2020 to January 2021. There was a total of 192 patients; 96 in the favipiravir group and 96in the non-favipiravir group (remdesivir/oseltamivir). Effectivity was measured by assessing the clinical condition at the end of the isolation period of 14 days. The favipiravir group showed better clinical conditions than the non-favipiravir group (79.2% vs. 56.3%; adjusted RR = 2.196; 95% CI = 1.084 – 4.451; p-value= 0.029), seen from being free of fever and respiratory problems. Stratification analysis demonstrated that the clinical improvement was significantly differentin the severe/critical group in favor of favipiravir (RR = 1.573; 95% CI = 1.139-2.172). The most common non-serious adverse events (AE) found in the use offavipiravir were gastrointestinal disturbances (12.5%). In brief, favipiravir is effective in severe/critical cases, and less serious AE were found in its use. Appropriate treatment is expected to help in reducing the public health burden.https://journal.fkm.ui.ac.id/kesmas/article/view/5433covid-19, effectivity, favipiravir, safety |
| spellingShingle | Herni Damayanti I Gede K Sajinadiyasa Hindun Wilda Risni Rani Sauriasari The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia Kesmas: Jurnal Kesehatan Masyarakat Nasional covid-19, effectivity, favipiravir, safety |
| title | The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia |
| title_full | The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia |
| title_fullStr | The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia |
| title_full_unstemmed | The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia |
| title_short | The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia |
| title_sort | effectiveness and safety of favipiravir in covid 19 hospitalized patients at tertiary referral hospital bali indonesia |
| topic | covid-19, effectivity, favipiravir, safety |
| url | https://journal.fkm.ui.ac.id/kesmas/article/view/5433 |
| work_keys_str_mv | AT hernidamayanti theeffectivenessandsafetyoffavipiravirincovid19hospitalizedpatientsattertiaryreferralhospitalbaliindonesia AT igedeksajinadiyasa theeffectivenessandsafetyoffavipiravirincovid19hospitalizedpatientsattertiaryreferralhospitalbaliindonesia AT hindunwildarisni theeffectivenessandsafetyoffavipiravirincovid19hospitalizedpatientsattertiaryreferralhospitalbaliindonesia AT ranisauriasari theeffectivenessandsafetyoffavipiravirincovid19hospitalizedpatientsattertiaryreferralhospitalbaliindonesia AT hernidamayanti effectivenessandsafetyoffavipiravirincovid19hospitalizedpatientsattertiaryreferralhospitalbaliindonesia AT igedeksajinadiyasa effectivenessandsafetyoffavipiravirincovid19hospitalizedpatientsattertiaryreferralhospitalbaliindonesia AT hindunwildarisni effectivenessandsafetyoffavipiravirincovid19hospitalizedpatientsattertiaryreferralhospitalbaliindonesia AT ranisauriasari effectivenessandsafetyoffavipiravirincovid19hospitalizedpatientsattertiaryreferralhospitalbaliindonesia |